Skip to main content
Premium Trial:

Request an Annual Quote

As Expected, Ciphergen Sells Chromatography Business to Pall for $32M

NEW YORK, Dec. 1 (GenomeWeb News) - Ciphergen has sold its BioSepra process-chromatography business to Pall for roughly $32 million.

 

The initial agreement to sell the business was announced in late October. As reported by GenomeWeb News at the time, the firms also entered into a collaboration under which New York-based Pall will establish process proteomics service centers to offer protein purification using BioSepra's chromatography products and Ciphergen's ProteinChip technology.

 

Ciphergen also said that it will retain certain limited rights to access BioSepra's chromatography sorbent technology for use in research and diagnostic markets.

 

Ciphergen recently reported a 31-percent decline in third-quarter revenue as sales of its ProteinChip mass spectrometry systems and BioSepra process chromatography products took a hit. The firm's loss for the quarter grew to $9.5 million, or $.33 per share, from a loss of $5.2 million, or $.18 per share, in the third quarter of 2003.

 

According to ProteoMonitor, a GenomeWeb News publication, the company predicted fourth-quarter revenue of between $11 million and $13 million. Of that amount, between $9.5 million and $11.5 million will be revenues that do not include BioSepra.

 

"The sale of our BioSepra process chromatography business allows us to focus our financial and business resources on our core research products and emerging diagnostic business," William Rich, CEO of Ciphergen, said in a statement announcing the third-quarter results. "The joint sales and marketing collaboration with Pall Corporation positions us to continue to sell the Protein Chip Systems into the process proteomics market."

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more